<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01741857</url>
  </required_header>
  <id_info>
    <org_study_id>NJGLYY005</org_study_id>
    <nct_id>NCT01741857</nct_id>
  </id_info>
  <brief_title>Umbilical Cord Derived Mesenchymal Stem Cells Transplantation for Active and Refractory Systemic Lupus Erythematosus</brief_title>
  <official_title>Phase I/II: Umbilical Cord Derived Mesenchymal Stem Cells Transplantation For Active And Refractory Systemic Lupus Erythematosus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will explore safety and efficacy of allogeneic umbilical cord (UC) derived
      mesenchymal stem cells transplantation (MSCT) to treat patients with active and refractory
      systemic lupus erythematosus (SLE) who have been resistant to multiple standard treatments.
      The underlying hypothesis is that the active SLE condition is caused by an abnormal immune
      homeostasis that can be restored by MSCT.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inclusion Criteria:

        1. All patients fulfilled the American College of Rheumatology (ACR) criteria of SLE, man
           or woman aged from 15 to 70 years old, SLEDAI≥8;

        2. Lupus nephritis with 24h urine protein≥1g;

        3. Refractory disease as determined by failure of the following regimens:

           Trial of corticosteroids (oral prednisone more than 20 mg/day); Trial of
           cyclophosphamide 0.4 ~ 0.6 / m2 every two weeks for six months, or other
           immunosuppressive drugs, such as mycophenolate mofetil 2 g / day, for three months;

        4. Patients must sign an informed consent indicating that they are aware of the
           investigational nature of the study in keeping with the policy of the hospital;

        5. Willing to use contraception throughout the study and for 12 months following treatment
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>British Isles Lupus Assessment Group score (BILAG)</measure>
    <time_frame>up to 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lupus serology (Alb, ANA, dsDNA, C3, C4)</measure>
    <time_frame>pre-MSC transplantation, 1, 3, 6 and 12 months post MSC transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function (GFR, Blood Urea Nitrogen, urinalysis)</measure>
    <time_frame>pre-MSC transplantation, 1, 3, 6 and 12 months post MSC transplantation (for GFR assessed at baseline and 12 months after MSCT)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>human umbilical cord derived MSC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>human umbilical cord derived MSC transplantation for SLE</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>human umbilical cord derived MSC transplantation for SLE</intervention_name>
    <arm_group_label>human umbilical cord derived MSC</arm_group_label>
    <other_name>Allogenic MSC derived from umbilical cord</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients fulfilled the American College of Rheumatology (ACR) criteria of SLE, man
             or woman aged from 15 to 60 years old, SLEDAI≥8;

          -  Lupus nephritis with 24h urine protein≥1g;

          -  Refractory disease as determined by failure of the following regimens:

        Trial of corticosteroids (oral prednisone more than 20 mg/day); Trial of cyclophosphamide
        0.4 ~ 0.6 / m2 every two weeks for six months, or other immunosuppressive drugs, such as
        mycophenolate mofetil 2 g / day, for three months;

          -  Patients must sign an informed consent indicating that they are aware of the
             investigational nature of the study in keeping with the policy of the hospital;

          -  Willing to use contraception throughout the study and for 12 months following
             treatment

        Exclusion Criteria:

          -  Abnormal liver function (ALT higher than 3 times the normal value);

          -  End-stage renal failure;

          -  Severe heart and pulmonary failure, or other important organs damage;

          -  Uncontrolled infections

          -  Pregnant or breast feeding women, male or female who intended to recent pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lingyun Sun, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>the Affiliated Drum Tower Hospital of Nanjing University Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Affiliated Drum Tower Hospital of Nanjing University Medical School</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sun</last_name>
      <phone>+86-25-83105209</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Sun L, Akiyama K, Zhang H, Yamaza T, Hou Y, Zhao S, Xu T, Le A, Shi S. Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. Stem Cells. 2009 Jun;27(6):1421-32. doi: 10.1002/stem.68.</citation>
    <PMID>19489103</PMID>
  </reference>
  <reference>
    <citation>Sun L, Wang D, Liang J, Zhang H, Feng X, Wang H, Hua B, Liu B, Ye S, Hu X, Xu W, Zeng X, Hou Y, Gilkeson GS, Silver RM, Lu L, Shi S. Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus. Arthritis Rheum. 2010 Aug;62(8):2467-75. doi: 10.1002/art.27548.</citation>
    <PMID>20506343</PMID>
  </reference>
  <reference>
    <citation>Liang J, Gu F, Wang H, Hua B, Hou Y, Shi S, Lu L, Sun L. Mesenchymal stem cell transplantation for diffuse alveolar hemorrhage in SLE. Nat Rev Rheumatol. 2010 Aug;6(8):486-9. doi: 10.1038/nrrheum.2010.80. Epub 2010 Jun 1.</citation>
    <PMID>20517294</PMID>
  </reference>
  <reference>
    <citation>Liang J, Zhang H, Hua B, Wang H, Lu L, Shi S, Hou Y, Zeng X, Gilkeson GS, Sun L. Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study. Ann Rheum Dis. 2010 Aug;69(8):1423-9. doi: 10.1136/ard.2009.123463. Erratum in: Ann Rheum Dis. 2011 Jan;70(1):237.</citation>
    <PMID>20650877</PMID>
  </reference>
  <reference>
    <citation>Zhang H, Zeng X, Sun L. Allogenic bone-marrow-derived mesenchymal stem cells transplantation as a novel therapy for systemic lupus erythematosus. Expert Opin Biol Ther. 2010 May;10(5):701-9. doi: 10.1517/14712591003769816. Review.</citation>
    <PMID>20345339</PMID>
  </reference>
  <reference>
    <citation>Shi D, Wang D, Li X, Zhang H, Che N, Lu Z, Sun L. Allogeneic transplantation of umbilical cord-derived mesenchymal stem cells for diffuse alveolar hemorrhage in systemic lupus erythematosus. Clin Rheumatol. 2012 May;31(5):841-6. doi: 10.1007/s10067-012-1943-2.</citation>
    <PMID>22302582</PMID>
  </reference>
  <reference>
    <citation>Che N, Li X, Zhou S, Liu R, Shi D, Lu L, Sun L. Umbilical cord mesenchymal stem cells suppress B-cell proliferation and differentiation. Cell Immunol. 2012;274(1-2):46-53. doi: 10.1016/j.cellimm.2012.02.004. Epub 2012 Feb 23.</citation>
    <PMID>22414555</PMID>
  </reference>
  <reference>
    <citation>Wang D, Akiyama K, Zhang H, Yamaza T, Li X, Feng X, Wang H, Hua B, Liu B, Xu H, Chen W, Shi S, Sun L. Double allogenic mesenchymal stem cells transplantations could not enhance therapeutic effect compared with single transplantation in systemic lupus erythematosus. Clin Dev Immunol. 2012;2012:273291. doi: 10.1155/2012/273291. Epub 2012 Jul 9.</citation>
    <PMID>22829849</PMID>
  </reference>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 26, 2012</study_first_submitted>
  <study_first_submitted_qc>December 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2012</study_first_posted>
  <last_update_submitted>November 1, 2013</last_update_submitted>
  <last_update_submitted_qc>November 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</investigator_affiliation>
    <investigator_full_name>Lingyun Sun</investigator_full_name>
    <investigator_title>Department of Rheumatology and Immunology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

